{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 64,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a numbered list format to present key company milestones and clinical data points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/3",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.87,
        "y": 0.03
      },
      "kind": "image",
      "text": "IMMIX BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c78fc1f-bc1e-47e1-9ed8-fcd0530b24ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.32,
        "y": 0.0016
      },
      "kind": "list",
      "text": "100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market); No drugs approved in relapsed/refractory AL amyloidosis today (29,712 U.S. patient prevalence); BCMA CAR-Ts are not created equal: NXC-201 designed for high activity in AL Amyloidosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc3a6f3a-1ba5-4c9d-b3af-c340a9461e30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.3,
        "x": 0.02,
        "y": 0.0016
      },
      "kind": "list",
      "text": "1. First CAR-T, NXC-201, in AL Amyloidosis\n2. Expanding into Additional Autoimmune indications\n3. First “single-day CRS” CAR-T\n4. NXC-201 n=73 patients across 11 peer-reviewed publications\n5. First CAR-T Overcoming Neurotoxicity\n6. IMX-110 - promising results in colorectal cancer with 30 patients dosed",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8397b993-47de-47fc-98b1-23c565deae11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.02,
        "y": 0.08
      },
      "kind": "title",
      "text": "NXC-201 FDA Investigational New Drug (IND) Application Already Cleared",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b6d45cc-8cce-4785-9657-9e2d63735467",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMMX: Autoimmune CAR-T Company with 73 patients dosed to-date",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0a26f7e-bfe0-45f3-97d6-64ac455562a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "26edcfc0-0da1-4b06-8b29-e1a4bc1b0a2c",
      "evidence": "list/numbered: 1. First CAR-T, NXC-201, in AL Amyloidosis...",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "5eb3fd04-a847-4966-a046-a4811b01abe5",
      "evidence": "The slide uses a numbered list to organize key company highlights.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "4664fc32-4b95-4b88-9160-8ea59df82e78",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "Slides 1-5 provide an overview of Immix Biopharma and the N-GENIUS Platform",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}